In addition, the mid-term results of the phase IB TATTON study, published at the AACR annual meeting in 2019, showed that the combination of osimertinib and savolitinib showed acceptable safety, and preliminary antitumor efficacy in patients with MET-amplified EGFR-mutant NSCLC treated with third-generation EGFR-TKIs [94]. This evidence concerns the gene MET and non-small cell lung carcinoma.